Chemoinformaics analysis of 4-Allylbenzene-1,2-diol
| Molecular Weight | 150.177 | nRot | 2 |
| Heavy Atom Molecular Weight | 140.097 | nRig | 7 |
| Exact Molecular Weight | 150.068 | nRing | 1 |
| Solubility: LogS | -1.588 | nHRing | 0 |
| Solubility: LogP | 1.975 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 21 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 10 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 23.3019 |
| nHD | 2 | BPOL | 10.0321 |
| QED | 0.498 |
| Synth | 2.166 |
| Natural Product Likeliness | 1.271 |
| NR-PPAR-gamma | 0.054 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0 |
| HIA | 0.008 |
| CACO-2 | -4.45 |
| MDCK | 0.000026 |
| BBB | 0.053 |
| PPB | 0.917181 |
| VDSS | 0.593 |
| FU | 0.043894 |
| CYP1A2-inh | 0.719 |
| CYP1A2-sub | 0.644 |
| CYP2c19-inh | 0.283 |
| CYP2c19-sub | 0.088 |
| CYP2c9-inh | 0.271 |
| CYP2c9-sub | 0.836 |
| CYP2d6-inh | 0.729 |
| CYP2d6-sub | 0.879 |
| CYP3a4-inh | 0.138 |
| CYP3a4-sub | 0.228 |
| CL | 18.398 |
| T12 | 0.918 |
| hERG | 0.007 |
| Ames | 0.467 |
| ROA | 0.645 |
| SkinSen | 0.935 |
| Carcinogencity | 0.719 |
| EI | 0.983 |
| Respiratory | 0.274 |
| NR-Aromatase | 0.02 |
| Antiviral | No |
| Prediction | 0.895849 |